Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial.

MLA

Rezvani, Hamid, et al. “Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-Blind, Noninferiority Clinical Trial.” Clinical Therapeutics, vol. 42, no. 5, May 2020, pp. 848–59. EBSCOhost, https://doi.org/10.1016/j.clinthera.2020.03.009.

APA

Rezvani, H., Mortazavizadeh, S. M., Allahyari, A., Nekuee, A., Najafi, S. N., Vahidfar, M., Ghadyani, M., Khosravi, A., Qarib, S., Sadeghi, A., Esfandbod, M., Rajaeinejad, M., Rezvani, A., Hajiqolami, A., Payandeh, M., Shazad, B., Anjidani, N., Meskinimood, S., Alikhasi, A., … Salari, S. (2020). Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial. Clinical Therapeutics, 42(5), 848–859. https://doi.org/10.1016/j.clinthera.2020.03.009

Chicago

Rezvani, Hamid, Seyed Mohammadreza Mortazavizadeh, Abolghasem Allahyari, Amirabbas Nekuee, Safa Najjar Najafi, Mohammadreza Vahidfar, Mojtaba Ghadyani, et al. 2020. “Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-Blind, Noninferiority Clinical Trial.” Clinical Therapeutics 42 (5): 848–59. doi:10.1016/j.clinthera.2020.03.009.